Toll-like receptor 7/8
Toll-like receptors 7 and 8 (TLR7 and TLR8) are single-stranded RNA (ssRNA)-sensing pattern recognition receptors (PRRs) belonging to the toll-like receptor family, a class of innate immune sensors critical for detecting pathogen-associated molecular patterns (PAMPs).
Toll-like receptors 7 and 8 (TLR7 and TLR8) are single-stranded RNA (ssRNA)-sensing pattern recognition receptors (PRRs) belonging to the toll-like receptor family, a class of innate immune sensors critical for detecting pathogen-associated molecular patterns (PAMPs). Both receptors are endosomal transmembrane glycoproteins expressed predominantly on immune cells, including dendritic cells, monocytes, macrophages, and B cells. TLR7 is preferentially expressed in plasmacytoid dendritic cells, while TLR8 shows higher expression in myeloid dendritic cells and monocytes. Upon binding to viral ssRNA or synthetic agonists, TLR7 and TLR8 signal through the MyD88 adaptor protein, activating NF-κB and IRF transcription factors to drive production of proinflammatory cytokines such as Interleukin-6 (IL-6), type I interferons, and other innate immune mediators. Their combined designation as TLR7/8 reflects substantial functional overlap, as dual agonists capable of engaging both receptors — most notably resiquimod (R848) — are widely used in research and clinical development.
TLR7 and TLR8 occupy a central position at the intersection of innate and adaptive immunity. Their activation potently stimulates dendritic cell maturation, enhances antigen cross-presentation, and promotes Th1-polarized adaptive immune responses, properties that have made TLR7/8 agonists attractive as vaccine adjuvants and cancer immunotherapy agents. Conversely, dysregulated or excessive signaling through these receptors — particularly gain-of-function mutations in TLR7 — has been implicated in autoimmune conditions including systemic lupus erythematosus (SLE), positioning TLR7/8 antagonists as a complementary therapeutic avenue. The dual nature of TLR7/8 as both immune activators and drivers of immunopathology makes them high-value targets across oncology, infectious disease, and autoimmunity research.
Where the papers sit
13 papers from the last 6 months study toll-like receptor 7/8 directly · updated from PubMed 16 Nov 2026
Study type 0 clinical trials · 1 human data · 11 preclinical · 1 unclassified
Themes one subject · 2 new directions
Those 13 are all about one subject.
-
Innate Immune Modulation
TLR7/8 modulation is being developed both as an innate immune stimulant and as a brake on autoimmune inflammation. Agonists are increasingly paired with TLR3, STING, tumor antigens, radiotherapy, ablation, or chemotherapy in nanovaccines and local delivery systems to activate dendritic cells, macrophages, and T-cell responses. The work is moving toward conditional activation and co-delivery platforms that improve tumor immunity while limiting systemic toxicity. Structure-based antagonists and TLR7-targeted microRNA strategies show that disease-specific suppression and immune restoration remain parallel goals, with clinical translation still open.
TLR7 can mediate a chemotherapy-responsive apoptotic-body pathway rather than serving only as a pharmacologic immune agonist
In chemotherapy-treated cancers and tumor-bearing mice, the study of thymosin alpha-1 and apoptotic bodies found that Tα-1 chaperones apoptotic-body miR-146a-5p into dendritic-cell endolysosomes, protects it from degradation, and enables it to activate TLR7, thereby licensing dendritic-cell maturation, tumor-antigen presentation, and CD8+ T-cell responses. This assigns TLR7 a previously unrepresented role in the set as an endogenous microRNA-sensing component of chemotherapy-induced antitumor immunity, with Tα-1 supplementation converting otherwise poorly immunogenic apoptotic material into an effective vaccine-like signal 42295795Jun.
TLR7 can function as a downstream effector of neuronal substance-P signaling that promotes oral-cancer progression
In orthotopic and subcutaneous oral squamous cell carcinoma models, the photosensitive ropivacaine/chlorin-e6 hydrogel study identified a dorsal-root-ganglion substance-P–Tacr1–Tlr7 axis that promotes metastasis and tumor progression through downstream PI3K/Akt signaling. Rather than treating TLR7/8 as an administered agonist or vaccine adjuvant, this work places TLR7 within neuro-tumoral crosstalk and shows that blocking neuronal substance-P release can suppress the axis and improve photothermal and photodynamic therapy, giving TLR7 a distinct neuroinflammatory role in cancer 42692233Sep.
Papers
The 13 papers from the last 6 months that study toll-like receptor 7/8 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Innate Immune Modulation (13)
- Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018605
- Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of controlled release : official journal of the Controlled Release Society · 24 Sept 2026 PMID 42785690
- Photosensitive ropivacaine- and chlorin e6-loaded hydrogel targeting the substance P-tachykinin receptor 1-toll-like receptor 7 axis enhances photodynamic and photothermal therapy against oral cancer. Acta biomaterialia · 3 Sept 2026 PMID 42692233
- Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of controlled release : official journal of the Controlled Release Society · 18 Aug 2026 PMID 42612875
- Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire. Journal of controlled release : official journal of the Controlled Release Society · 13 Aug 2026 PMID 42595179
- Vitamin B2 Derivative-Enabled Sonochemical Thioketal Cleavage for Ultrasound-Activated In Situ Tumor Vaccination. Nano letters · 12 Aug 2026 PMID 42584258
- Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
- Nanodisc-Forming Polymers as TLR7/8 Agonist-Conjugated Immunotherapy Agents. Biomacromolecules · 16 Jul 2026 PMID 42463976
- A Liposomal Nanovaccine Reprograms Post-Ablation Macrophages to Sustain Antitumor Immunity in Hepatocellular Carcinoma. Acta biomaterialia · 15 Jul 2026 PMID 42457009
- Injectable Thermal-Protective Hydrogel Enables Curative Tumor Ablation via Chemo-Immunomodulation. ACS applied materials & interfaces · 30 Jun 2026 PMID 42374665
- Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research · 15 Jun 2026 PMID 42295795
- Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843
By study type
Human data, design not indexed (1)
- Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843
Preclinical: animal, cell and lab studies (11)
- Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018605
- Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of controlled release : official journal of the Controlled Release Society · 24 Sept 2026 PMID 42785690
- Photosensitive ropivacaine- and chlorin e6-loaded hydrogel targeting the substance P-tachykinin receptor 1-toll-like receptor 7 axis enhances photodynamic and photothermal therapy against oral cancer. Acta biomaterialia · 3 Sept 2026 PMID 42692233
- Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of controlled release : official journal of the Controlled Release Society · 18 Aug 2026 PMID 42612875
- Vitamin B2 Derivative-Enabled Sonochemical Thioketal Cleavage for Ultrasound-Activated In Situ Tumor Vaccination. Nano letters · 12 Aug 2026 PMID 42584258
- Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
- Nanodisc-Forming Polymers as TLR7/8 Agonist-Conjugated Immunotherapy Agents. Biomacromolecules · 16 Jul 2026 PMID 42463976
- A Liposomal Nanovaccine Reprograms Post-Ablation Macrophages to Sustain Antitumor Immunity in Hepatocellular Carcinoma. Acta biomaterialia · 15 Jul 2026 PMID 42457009
- Injectable Thermal-Protective Hydrogel Enables Curative Tumor Ablation via Chemo-Immunomodulation. ACS applied materials & interfaces · 30 Jun 2026 PMID 42374665
- Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research · 15 Jun 2026 PMID 42295795
Unclassified: not yet indexed with MeSH (1)
- Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire. Journal of controlled release : official journal of the Controlled Release Society · 13 Aug 2026 PMID 42595179
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.